Last reviewed · How we verify

short-course antibiotic treatment

Rabin Medical Center · Phase 1 active Small molecule

short-course antibiotic treatment is a Small molecule drug developed by Rabin Medical Center. It is currently in Phase 1 development.

At a glance

Generic nameshort-course antibiotic treatment
SponsorRabin Medical Center
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about short-course antibiotic treatment

What is short-course antibiotic treatment?

short-course antibiotic treatment is a Small molecule drug developed by Rabin Medical Center.

Who makes short-course antibiotic treatment?

short-course antibiotic treatment is developed by Rabin Medical Center (see full Rabin Medical Center pipeline at /company/rabin-medical-center).

What development phase is short-course antibiotic treatment in?

short-course antibiotic treatment is in Phase 1.

Related